Search
Search Results
-
Coronary no-reflow and adverse events in patients with acute myocardial infarction after percutaneous coronary intervention with current drug-eluting stents and third-generation P2Y12 inhibitors
BackgroundThe frequency and prognostic value of coronary no-reflow (CNR) was investigated in studies that have used an outdated reperfusion therapy...
-
Translation of experimental cardioprotective capability of P2Y12 inhibitors into clinical outcome in patients with ST-elevation myocardial infarction
We studied the translational cardioprotective potential of P2Y 12 inhibitors against acute myocardial ischemia/reperfusion injury (IRI) in an animal...
-
P2Y12-dependent activation of hematopoietic stem and progenitor cells promotes emergency hematopoiesis after myocardial infarction
Emergency hematopoiesis is the driving force of the inflammatory response to myocardial infarction (MI). Increased proliferation of hematopoietic...
-
Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose–Response
PurposeThis study aims to assess the association between body mass index ( BMI ) and platelet reactivity in STEMI patients treated with oral 3 rd ...
-
Influence of Genetic and Epigenetic Factors of P2Y12 Receptor on the Safety and Efficacy of Antiplatelet Drugs
PurposeP2Y 12 receptor inhibitors are drugs that decrease the risk of stent thrombosis and lower the long-term risk of non-stent-related myocardial...
-
P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention
For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y 12 receptor inhibitor, has been the gold...
-
Comparing angiotensin receptor–neprilysin inhibitors with sodium–glucose cotransporter 2 inhibitors for heart failure with diabetes mellitus
Background and aimsClinical comparisons of angiotensin receptor–neprilysin inhibitors (ARNI) and sodium–glucose cotransporter 2 inhibitors (SGLT2i)...
-
Meta-Analysis Comparing Potent Oral P2Y12 Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
BackgroundIn patients with atrial fibrillation (AF) receiving percutaneous coronary intervention (PCI), current guidelines recommend against...
-
Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation
Background and ObjectiveRecent research indicates a correlation between plasma concentration of P2Y12 inhibitors and clinical events, particularly...
-
Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists
In this prospective, 3-arm, repeated-measure multicenter investigation in 280 patients with cardiovascular risk factors, platelet aggregation was...
-
Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study
PurposeChronic kidney disease (CKD) is a risk factor for ischemic and bleeding events with dual antiplatelet therapy after percutaneous coronary...
-
Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry
BackgroundDespite the advances of potent oral P2Y 12 inhibitors, their onset of action is delayed, which might have a negative impact on clinical...
-
Verifynow P2Y12 PRU-Guided Modification of Clopidogrel for Prevention of Recurrent Ischemic Stroke: A Real-World Prospective Cohort Study
IntroductionClopidogrel resistance causes recurrent stroke. However, outcomes of modified antiplatelet medications to prevent recurrent ischemic...
-
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis
Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes undergoing percutaneous coronary intervention comprises...
-
Efficacy and Safety of Potent Oral P2Y12 Inhibitors in Medically Managed ACS Patients: a Meta-analysis
PurposeAlthough current guidelines recommend ticagrelor in addition to aspirin as the antiplatelet strategy for medically managed acute coronary...
-
Exploring Medication Adherence with P2Y12 Inhibitors Using Conditional and Unconditional Quantile Regression Approaches
BackgroundPrevious research assessing medication adherence with P2Y 12 inhibitors has shown good adherence rates, ranging from 78% to 92%. Studies...
-
The risk of dyspnea in patients treated with third-generation P2Y12 inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials
BackgroundTicagrelor and prasugrel are two third-generation oral P2Y 12 inhibitors which are more commonly used in clinical practice. However,...
-
Cost-Effectiveness of Strategies to Personalize the Selection of P2Y12 Inhibitors in Patients with Acute Coronary Syndrome
PurposePerform a cost-effectiveness analysis comparing strategies for selecting P2Y 12 inhibitors in acute coronary syndrome (ACS).
Methods ...
-
Personalized Dual Antiplatelet Therapy in Acute Coronary Syndromes: Striking a Balance Between Bleeding and Thrombosis
Purpose of ReviewDual antiplatelet therapy (DAPT)—aspirin in conjunction with a P2Y 12 inhibitor—is the cornerstone of managing patients with acute...
-
Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease
Balancing the safety and efficacy of antithrombotic agents in patients with gastrointestinal disorders is challenging because of the potential for...
